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ABSTRACT
Objective: There are currently no effective treatments to halt the muscle breakdown in Duch-
enne muscular dystrophy (DMD), although genetic-based clinical trials are being piloted. Most
of these trials have as an endpoint the restoration of dystrophin in muscle fibers, hence re-
quiring sufficiently well-preserved muscle of recruited patients. The choice of the muscles to
be studied and the role of noninvasive methods to assess muscle preservation therefore re-
quire further evaluation.
Methods: We studied the degree of muscle involvement in the lower leg muscles of 34 patients
with DMD 8 years, using muscle MRI. In a subgroup of 15 patients we correlated the muscle
MRI findings with the histology of open extensor digitorum brevis (EDB) muscle biopsies. Muscle
MRI involvement was assigned using a scale 0–4 (normal–severe).
Results: In all patients we documented a gradient of involvement of the lower leg muscles: the
posterior compartment (gastrocnemius  soleus) was most severely affected; the anterior com-
partment (tibialis anterior/posterior, popliteus, extensor digitorum longus) least affected. Muscle
MRI showed EDB involvement that correlated with the patient’s age (p  0.055). We show a
correlation between the MRI and EDB histopathologic changes, with MRI 3–4 grades associated
with a more severe fibro-adipose tissue replacement. The EDB was sufficiently preserved for bulk
and signal intensity in 18/22 wheelchair users aged 10–16.6 years.
Conclusion: This study provides a detailed correlation between muscle histology and MRI
changes in DMD and demonstrates the value of this imaging technique as a reliable tool for the
selection of muscles in patients recruited into clinical trials. Neurology® 2011;76:346–353
GLOSSARY
AO  antisense oligonucleotide; DMD  Duchenne muscular dystrophy; EDB  extensor digitorum brevis; KAFO 
knee-ankle-foot orthosis; NSA number of signal averages; TE echo time; TR repetition time.
The progressive loss of muscle fibers and their replacement by fat and connective tissue is part
of the disease course of DMD.1 Despite several exhaustive natural history studies on the clinical
course of DMD, the progression of pathology in individual muscle groups is poorly defined.2
Information on muscle pathology in DMD is limited to the muscles that are biopsied at the
time of diagnosis (often quadriceps femoris),2 the mean age at diagnosis being 4.5 years.3,4
There are now early clinical trials using novel genetic-based techniques in boys with DMD
with the aim to restore dystrophin expression. These include the drug PTC124,5 which allows
From The Dubowitz Neuromuscular Centre (M.K., V.A.-G., S.C., L.F., A.Y.M., E.M., J.E.M., C.S., F.M.), Institute of Child Health, London;
Departments of Paediatrics (M.K., S.C., A.N., L.H.-C., A.Y.M., F.M.) and Radiology (A.G.), Hammersmith Hospital, London; Newcastle University
(M.G., V.S., K.B.), Institute of Human Genetics, Newcastle; Newcastle Magnetic Resonance Centre (K.G.H.), Institute of Cellular Medicine,
Newcastle University, Newcastle; Department of Orthopaedics (D.H.), St. Mary’s Hospital, London; Department of Paediatric Neurology (H.J.),
Evelina Children’s Hospital, Guy’s & St. Thomas’ Hospital NHS Foundation Trust, London; Clinical Neuroscience Division (H.J.), King’s College,
London; Birmingham Heartlands Hospital (H.P.R.), Birmingham; MRC Centre for Neuromuscular Diseases (R.M.Q.), The National Hospital for
Neurology and Neurosurgery, Queen Square, London; The Dubowitz Neuromuscular Centre (R.M.Q.), Great Ormond Street Hospital, London;
Wolfson Centre for Inherited Neuromuscular Disorders (C.S.), Robert Jones and Agnes Hunt NHS Trust, Oswestry; Department of Paediatric
Neurology (J.A.G.), Leicester Royal Infirmary, University Hospitals of Leicester, Leicester; Department of Paediatric Neurology (S.J.), Oxford
Children’s Hospital, UK; Pediatric Neurology Unit (E.M.), Catholic University, Rome, Italy; and Robert Steiner MRI Unit (M.R.), Hammersmith
Hospital, Imperial College London, UK.
Study funding: Supported by the Department of Health, UK, and run in partnership with the following charitable organizations: Muscular Dystrophy
Campaign, Action Duchenne, and Duchenne Family Support Group.
Disclosure: Author disclosures are provided at the end of the article.
Address correspondence and
reprint requests to Dr. Francesco
Muntoni, The Dubowitz
Neuromuscular Centre, First
Floor, UCL Institute of Child
Health, 30 Guilford Street,
London, UK
f.muntoni@ich.ucl.ac.uk
346 Copyright © 2011 by AAN Enterprises, Inc.
read-through of nonsense mutations, and an-
tisense oligonucleotides (AOs), which induce
exon skipping and restore the reading frame
in boys with out-of-frame deletions.6,7 These
early trials require selection of sufficiently
well-preserved muscles for the evaluation of
induced dystrophin production, which is the
primary outcome assessed.8 Recently MRI has
been used for quantification of atrophy of the
small foot muscles in chronic patients with
diabetic neuropathy.9,10
We have recently completed a phase Ib/IIa
clinical trial showing restoration of dystro-
phin expression by using IM injection of a
morpholino AO (AVI-4658) in a group of
boys with DMD with deletions that can be
rescued by skipping exon 51.11
In order to make an informed selection of
the muscle to inject in this trial, we assessed
the degree of muscle involvement of leg and
foot muscles in patients with DMD using
muscle MRI. In a subset of patients we corre-
lated muscle MRI findings with histopatho-
logic analysis of open muscle biopsies from
the extensor digitorum brevis muscle (EDB),
taken under anesthesia at the time of planned
orthopedic surgery. We hypothesized that
MRI findings would correlate with muscle
histopathology, and this correlation in DMD
is not well-established. We also correlated
MRI changes of the EDB muscles with the
age and time in years since loss of indepen-
dent ambulation for those patients who were
wheelchair-dependent.
METHODS The two sites (Dubowitz Neuromuscular Centre
in London and Newcastle University) involved in this prepara-
tory work are two of the major centers for care of pediatric neu-
romuscular patients in the United Kingdom. Both sides are part
of the UK MDEX consortium (http://www.mdex.org.uk/), in-
volved in experimental therapy for DMD. This preparatory
study was approved by a Multicenter Ethics Committee in the
United Kingdom.
All boys with DMD studied with muscle MRI were over 8
years of age and had their diagnosis established by either DNA
mutation analysis or muscle biopsy, or both. In a subset of boys
undergoing elective surgery, we obtained a muscle biopsy of the
EDB muscle. We excluded patients with severe cardiorespiratory
involvement (forced vital capacity 25% predicted [according
to the arm span or height] and a fractional shortening 25% or
ejection fraction40%) as this would have been a contraindica-
tion to planned surgery. We also excluded patients with severe
cognitive dysfunction and inability to collaborate with the as-
senting procedure. Informed consent was obtained from patients
older than 16 years. Patients younger than 16 years gave their
assent, and consent was obtained from their parents/carers. We
collected the following clinical information:
• Mobility status at the time of the study if still ambulant
and age/years since loss of independent ambulation if not
ambulant.
• Dystrophin gene mutation analysis.
• Reports from diagnostic muscle biopsies, detailing dystro-
phin expression.
Muscle MRI. As part of our study protocol, we performed a
muscle MRI of the limb muscles (foot and below the knee) on all
our patients.11 The boys did not receive any sedation and the
total examination time was less than 30 minutes.
MRI sequences were optimized using volunteers to deter-
mine the best one for displaying the EDB muscle, using a con-
ventional T1-weighted spin echo on either a 1.0-T or a 3-T
Philips scanner system. Noncontrast enhanced images were ob-
tained from both legs (below the knees and feet).
To study the distal leg muscles (below knees) we used a body
coil for obtaining T1 spin echo, in the transverse plane, 15 slices
each leg, thickness 5 mm each, and the gap between slices varied
from 10 to 50 mm dependent on the site and on the size of the
patient. The axial plane was selected with respect to the long axis
of the body. A spin echo pulse sequence was used (repetition
time [TR]  500 msec; echo time [TE]  20 msec) with a
256  256 matrix, number of signal averages (NSA)  1, and a
variable field of view of 25–50 cm.
To study the feet, we used a head coil with a closed end and a
T1 volume-weighted sequence in the sagittal plane, to obtain
approximately 120 slices, thickness 0.8 mm each, with a total
acquisition time of 8 minutes. A spin echo pulse sequence was
used (TR 30 msec; TE 4.5 msec) with a 256 156 matrix,
NSA  1, and a flip angle 30. Only one foot was placed in the
coil each time.
For the muscle MRI below the knees, sections were generally
analyzed within the midupper section of the lower legs, as muscle
bulk is greatest at this level and muscle abnormality could be
more clearly visualized as a result. The EDB is a broad, thin
intrinsic foot muscle located on the dorsum of the foot immedi-
ately under the skin. The EDB arises from the lateral talocalca-
nean ligament and from the common limb of the cruciate crural
ligament (figure 1). It attaches on the phalanges of the second to
fifth toes. Care was taken to review in all muscles the remainder
of the muscle bulk in order to confirm that the analyzed section
was representative of the whole muscle.
Muscle MRI scans were assessed for normal and abnormal
(atrophy/hypertrophy) muscle bulk and for normal and abnor-
mal signal intensity within the different muscle groups and in
particular the EDB muscle of both feet. All muscle MRI scans
were assessed by 2 independent observers (M.K., M.R.), and
scored as follows12:
Stage 0: Normal appearance
Stage 1: Scattered small areas of increased density
Stage 2a: Numerous discrete areas of increased density
less than 30% of the volume of the muscle
Stage 2b: Numerous discrete areas of increased density with
early confluence, 30%–60% of the volume of the muscle
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Stage 3: Washed-out appearance due to confluent areas in-
creased density with muscle still present at the periphery
Stage 4: End-stage appearance, muscle entirely replaced by
areas of increased density
EDB open muscle biopsy. An open biopsy of the EDB mus-
cle was obtained within 0–8 months form the muscle MRI in 16
patients who underwent planned surgery. The biopsies were ob-
tained either at the time of surgery to release contractures of the
Achilles tendons or improve foot deformities (triple foot arthro-
desis) when older than 10 years of age or during spinal surgery.
The latter is usually performed at around 13–14 years of age or
later.13 The remaining patients did not undergo EDB biopsy. For
the EDB biopsy, an incision was drawn longitudinally between
the lateral malleolus and the tuberositas of the fifth metatarsal
bone following clinical examination. EDB muscle biopsy speci-
mens were investigated in our routine diagnostic pathology lab-
oratory. Muscle histology was scored by 2 independent observers
(C.A.S., L.F.) in transverse sections; the observers scored sepa-
rately and reached agreement after discussion, according to the
following protocol14:
Grade 1: Retention of fascicular pattern with no obvious
proliferation of fat or connective tissue
Grade 2: Retention of fascicular pattern plus invasion by
connective tissue and/or fat proliferation
Grade 3: Disruption of muscle fascicles with marked connec-
tive tissue and/or fat proliferation
Grade 4: Severe change with replacement of more than
50% of muscle by fat and connective tissue
Considering that the observed MRI changes could have also
been influenced by fatty infiltration of the EDB muscle, we
scored the EDB fat content according to the following criteria:
Grade 1:Only single adipocytes visible, well-preserved fascicles
Grade 2: Perimysial adipocytes visible with preserved fascicle
structure
Grade 3: Numerous perimysial and endomysial adipocytes
with loss or partial loss of fascicular structure
Grade 4: Pronounced fatty replacement throughout with
fascicle structure lost
Genetic mutations. The endpoints of the deletions in the
DMD gene were defined in all patients using genomic DNA
isolated from blood. Most patients had out-of-frame deletions, 3
had nonsense mutations, and one a splice site mutation leading
to an out-of-frame RNA deletion.
Statistics. Descriptive statistics were carried out wherever ap-
propriate by using the Graph Pad prism 4 program. We also
correlated the changes in the MRI of the EDB muscles with the
age of the patient and the years since loss of independent ambu-
lation. Both correlations were tested using the Spearman rank
order correlation coefficient.
We also correlated the scoring of EDB muscles using both
MRI and histopathologic grades using the Spearman rank coeffi-
cient rs.
RESULTS Thirty-four patients with DMD partici-
pated in this study. Thirty-two of them had muscle
MRI investigations of both lower legs and both feet;
one patient did not have an MRI of his feet and a
further patient did not have an MRI of his calves.
Fifteen patients (mean age 12.16  2.15 years) also
had EDB biopsies within 0–8 months (2  2) from
their muscle MRI studies, allowing the correlative
MRI and EDB studies. One patient had an EDB
biopsy (subject 1) but did not have a foot MRI so
correlation was not possible. The table shows the
overall population studied in relation to their age,
mobility, DMD gene mutation. and EDB biopsies
obtained with scoring of EDB muscles using both
MRI and histopathologic scores.
MRI. Both observers (M.K., M.R.) had a training
session ahead of scoring the muscle MRI scans. Inter-
observer agreement was reached in all subjects.
Calf muscles. The posterior compartment was most
severely affected (gastrocnemius soleus). The ante-
rior compartment was least affected (tibialis anterior/
posterior, popliteus, extensor digitorum longus)
(figure 2). The state of preservation of the anterior
compartment muscles and in particular the tibialis
anterior/posterior was similar to the EDB in all patients
studied (n  33). Conversely, the state of preservation
of the posterior muscles (gastrocnemius  soleus) was
always more advanced than the EDB muscles in all pa-
tients studied (n 33).
Foot muscles. The mean age of the 33 patients stud-
ied was 12.51  2.47 years (table). Muscle MRI
showed that the EDB muscles were always identifi-
able despite their small dimensions and had variable
levels of signal changes (figure 2). Five patients were
either using knee-ankle-foot orthoses (KAFOs, n 
Figure 1 Sagittal plane of the foot with the anatomic markings of the talus
and the forepart of the upper and lateral surfaces of the
calcaneus in a control subject
(A) Talus, (B) extensor digitorum brevis, (C) calcaneus.
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Table Patients studied, their mobility status, and Duchenne gene deletion and scoring of EDBmuscles using bothMRI and histopathologic
grades
Subjects
studied
Age at
study Functional abilities MRI muscle
MRI EDB
changes
Dystrophin gene
mutation
EDBmuscle biopsy
scoring histology
score/fat score
1 13 y WC since 9 y BK NA Stop mutation exon 70
(c.10171CT;
p.R3391X)
2/1
2 11 y 3 mo WC since 11 y 2 mo EDB and BK Grade 2b Del 45–52 NA
3 9 y 10 mo KAFOs standing since 8 y EDB and BK Grade 2b Del 46–50 NA
4 9 y Walking with difficulties EDB and BK Grade 1 Del 61 NA
5 11 y 10 mo WC since 11 y 5 mo EDB and BK Grade 3 Del 46–49 NA
6 15 y KAFOs standing since 10 y EDB and BK Grade 4 Del 46–50 NA
7 9 y 8 mo Standing since 9 y EDB and BK Grade 2a Del 47–50 NA
8 12 y 11 mo WC since 10 y EDB and BK Grade 2b Del 46–52 2/2
9 11 y 4 mo WC since 7 y EDB and BK Grade 2b Del 3–13 2/2
10 15 y 9 mo WC since 12 y EDB and BK Grade 3 Stop mutation exon 53
(c.7720CT;
p Q2574X)
4/3
11 10 y WC since 9 y EDB and BK Grade 4 Del 44 3/3
12 8 y 7 mo Walking with difficulties EDB Grade 2a Del 51–53 2/2
13 11 y WC since 9 y EDB and BK Grade 2b Del 45–52 3/3
14 17 y 7 mo WC since 11 y 8 mo EDB and BK Grade 4 Del 50 NA
15 12 y 3 mo WC since 8 y 9 mo EDB and BK Grade 3 Del 46–51 3/3
16 12 y 5 mo KAFOs walking 20 steps EDB and BK Grade 2a Del 45–52 NA
17 12 y 5 mo Cruises indoors 5–10 steps EDB and BK Grade 2a Del 46–50 NA
18 16 y WC since 10 y EDB and BK Grade 2a Stop mutation exon 50
c.7437GA;
p.E2460X
NA
19 13 y 8 mo WC since 11 y 10 mo EDB and BK Grade 3 Del 45 NA
20 12 y WC since 11 y EDB and BK Grade 2b Del 46–49 2/2
21 16 y 3 mo WC since 11 y EDB and BK Grade 2a c.7201-1_7201-14del
Intron 49/splice site
exon 50
2/3
22 12 y 9 mo WC since 10 y 1 mo, but rides
static bike 10 min daily
EDB and BK Grade 2b∞/
grade 3
Del 50 2/3
23 16 y 7 mo WC since 15 y 7 mo and
supported standing
30 min/day
EDB and BK Grade 2b Del 45–50 NA
24 15 y 6 mo WC since 8 y 2 mo EDB and BK Grade 4 Del 46–50 NA
25 15 y 4 mo WC since 12 y EDB and BK Grade 2b Del 48–50 NA
26 12 y WC since 8 y 6 mo EDB and BK Grade 3∞/
grade 2a
Del 45–50 NA
27 11 y 7 mo WC since 10 y EDB and BK Grade 2b∞/
grade 3
Del 48–50 3/3
28 15 y Walks indoors EDB and BK Grade 2a∞/
grade 2b
Del 48–50 2/2
29 10 y 9 mo Walks independently EDB and BK Grade 1 Del 45–50 2/2
30 11 y 9 mo Walks independently EDB and BK Grade 2b Del 47–50 NA
31 12 y 3 mo Walks independently EDB and BK Grade 2a Del 45–50 2/2
32 8 y 5 mo Walks independently EDB and BK Grade 2b Del 45–50 NA
33 12 y Walks independently EDB and BK Grade 2b Del 49–50 NA
34 10 y Walks independently EDB and BK Grade 1 Del 49–50 2/2
Abbreviations: ∞ asymmetric extensor digitorum brevis involvement on muscle MRI grading; BK below knee; EDB extensor digitorum brevis; KAFO
knee-ankle-foot orthosis; NA sample not obtained; WCwheelchair.
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3) or cruising/standing indoors (n 2) at the time of
the study. A further 9 patients were walking inde-
pendently, 3 with difficulties. Only 4 patients had
severe end-stage changes of the EDB (grade 4).
Two of them were 15.5 years and a further 1 17.6
years although a younger 10-year-old patient had
similar changes (figure 2, table). The majority of
the remaining patients had relatively good preser-
vation of their EDB muscles (grades 2a–2b), in-
cluding 5 patients older than 15 years. Two
patients had very mild changes (grade 1) while
they were still ambulant (figure 2). Six patients
had asymmetric involvement of the EDB as judged
by the MRI changes. Of those, 2/6 were able to
walk indoors, 1 patient walked with KAFOs, and
3/6 patients were wheelchair users.
Correlation between MRI and clinical findings (age of
the patient and years since loss of ambulation). The
muscle MRI showed a progressive involvement of the
EDB, which was more obvious in older patients and
in those who had lost ambulation for a longer time.
We observed a correlation of MRI score with increas-
ing age (figure 3A) (p  0.055, n  33, rs  0.29)
and this was also reflected in the correlation between
the time in years since loss of independent ambula-
tion and EDB MRI changes, although this did not
reach significance (p  0.18, n  22, rs  0.2).
EDB histology. Fifteen of 16 patients had relatively
good preservation of their EDB muscles on histology
(grade 2, n 10, grade 3, n 4). One patient older
than 15 years had severe changes (grade 4) (table).
Furthermore, we scored the fatty replacement in the
EDB muscle separately as described above: in only 2
samples there was a difference between the fat score
and the overall histology score (table).
Correlation between MRI and EDB histopathologic
findings. There was a good correlation between the
MRI and the EDB histopathology in 10/15 of the
patients studied with both MRI and EDB biopsies
(figure 3B) (p  0.001, n  15, rs  0.812). The
correlation between MRI scores and EDB fat score
was also significant (figure 3C) (p  0.05, n  15,
rs  0.62). Muscle MRI and histology correlative
studies shows that MRI grading 2–3 was associated
with sufficiently preserved EDB structure (grade 2 in
11 patients and grades 2/3 or 3 in 3 patients). MRI
grades 3 and 4 were associated with a more fibroadi-
pose tissue replacement (figure 2, table).
DISCUSSION Muscle MRI is being increasingly
used as a diagnostic tool as various inherited neuro-
muscular disorders show a specific pattern of muscle
involvement.15 In DMD, T1-weighted images show
a progressive and selective pattern of involvement
with fatty infiltration of the lower limb muscles when
boys are older than 6–7 years,16,17 but correlative
MRI–histologic studies are lacking. Our study was
designed to ascertain the involvement of the
EDB muscles in a population of boys with DMD
using muscle MRI, and to obtain correlations be-
tween muscle MRI and histologic changes in a subset
of these boys with DMD. This preparatory study was
Figure 2 Progressive involvement of the extensor digitorum brevis (EDB) muscle onMRI grading (patients from left to right)
Good correlation between the muscle MRI scoring of the EDB and tibialis anterior/posterior muscles. Grade 4 EDB was not obtained; see the table. H&E
hematoxylin-eosin.
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also designed to validate muscle MRI as a tool to
allow the selection of patients with sufficiently pre-
served EDB muscle for IM injection of an AO.11
Our results indicate that the EDB was relatively
well-preserved in most patients, even in the nonam-
bulant ones. All but four of our patients had suffi-
ciently preserved (grade 1–3 changes) EDB muscles
by MRI, despite 22 having lost the ability to walk for
a period of 2.9 (2) years. End-stage appearance
(grade 4), with the EDB muscle being completely
replaced by increased density connective tissue and
fat, was however documented in 4 patients (2 of
them were 15.5 years and a further 2 17.6 years and
10 years), all nonambulant. In the population of
boys with DMD studied, there was a significant cor-
relation between the EDB MRI grading and a corre-
lation between the EDB MRI changes and the years
since loss of ambulation. Our data complement those
of a previous study demonstrating a good correlation
between MRI grading of the lower limb muscles
(thighs and calves) and the patients’ clinical function
as well as their disease duration.18 Nevertheless, indi-
vidual patients showed unexpected relative preserva-
tion (grade 2 changes) on MRI grading despite
advanced age (mean age 16 years, mean 4 years since
loss of ambulation). In 6 patients there was an asym-
metric MRI involvement with regard to muscle bulk
and structural changes, with 1 of the 2 EDB muscles
being slightly better preserved (mostly grades 2a/2b).
Asymmetric individual muscle involvement has been
described in the lower limb muscles of patients with
DMD in a single previous study, a finding due to the
high resolution of muscle MRI.18 We did not observe
any obvious asymmetric involvement in the trans-
verse sections of the below the knees muscle groups
in our cohort, although this is a phenomenon that
can be found in female manifesting carriers of
DMD.19 We have not found any patient with absent
EDB muscles, which is a normal but very rare varia-
tion in the general population.20
The overall changes in the lower leg muscle
groups were always more advanced compared to the
foot muscles. The anterior compartment such as the
tibialis anterior and posterior, popliteus, and exten-
sor digitorum longus appeared better preserved than
the posterior compartment. In particular, the MRI
changes of the tibialis anterior and posterior were
very similar to the EDB, whereas the muscles of the
posterior compartment (gastrocnemius and soleus)
had advanced changes, mostly grade 3–4. A similar
pattern of muscle involvement has been previously
reported in T1-weighted studies from patients with
DMD with advanced disease.21–23
We finally correlated the extent of histologic mus-
cle pathology, in our case the EDB muscle, with the
corresponding muscle MRI involvement. These
EDB histopathologic changes correlated well with
the MRI changes in 10 of 15 patients in whom EDB
biopsies and MRI were available. As increased signal
intensity on T1 images may reflect increase in fibrous
tissue or in adipose tissue, we also independently
scored the presence of adipose tissue in the muscle
biopsies, but this did not improve the correlation ob-
served when the extent of the fibrosis was considered.
Our correlative histology/imaging studies therefore
suggest that MRI grading 2–3 is associated with suf-
ficiently preserved structure, typically grade 2 of his-
tologic changes. Muscle MRI overestimated the
structural EDB changes in 2 patients and apparently
underestimated them in another 3 patients. This
finding might be related to technical difficulties in
reproducing and scoring exactly the same section de-
lineation for both MRI and EDB histopathologic
studies. One of the limitations is that the EDB bi-
Figure 3 Correlation between clinical, pathologic, andMRI findings
(A) Correlation between the patient’s age at the time of the extensor digitorum brevis (EBD) biopsy and the EDB MRI score. (B) Correlation between the EDB
MRI score and the EDB histology score. (C) Correlation between the EDB fat score and the EDB MRI score.
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opsy (measuring approximately 2  2  0.5 cm)
needs to be mounted in order to be processed, trim-
ming the border of the sample and orienting the
muscle transversally. It is possible that during the
trimming process areas of perimysial fat have been
removed. Regarding the muscle MRI technique used
here, we only used a short protocol with T1 se-
quences. The use of a longer examination using fat
suppression sequences or 3-point Dixon techniques
to quantify fibrous tissue might have helped us to
obtain further information.24 However, this would
have required a considerably longer examination
time and the need for sedation or general anesthesia
in several cases, which we did not want to perform.
Despite these limitations, in most patients our correl-
ative studies were accurate, which suggests that this
muscle MRI protocol has a potential application in
assessing the preservation of various muscles without
having to verify this invasively.
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